SCHEDULE 13G/A
Statement of Beneficial Ownership
Lexeo Therapeutics, Inc. Filed Acc 0000902664-26-004577
Stakes reported in this filing
| Reporting person | Shares | Of the class |
|---|---|---|
| Vestal Point Capital, LP | 5,187,302 | 6.3% |
| Ryan Wilder | 5,187,302 | 6.3% |
Members of a group can each report the same shares, so these rows overlap and don't add up.
Stake history · largest stake in each 13D and 13G
- 2026-11-16 SCHEDULE 13G/A · JANUS HENDERSON GROUP Ltd. 7.2%
- 2026-11-16 SCHEDULE 13G/A · BALYASNY ASSET MANAGEMENT L.P. 9.99%
- 2026-11-16 SCHEDULE 13G/A · Paradigm BioCapital Advisors LP 0.0%
- 2026-11-16 SCHEDULE 13G/A · Vestal Point Capital, LP 6.3%
- 2026-11-13 SCHEDULE 13G/A · Affinity Asset Advisors, LLC 9.8%
Loading xslSCHEDULE_13G_X02/primary_doc.xml…